Efter en kommende succesfuld notering på Nasdaq i New York venter det Hellerup-baserede selskab, der arbejder med behandling af væksthormon-problemer, at have kontanter for op mod 1 mia. kr. ”We estimate that the net proceeds from this offering will be approximately $75.1 million, or approximately $86.9 million if the underwriters exercise their option to subscribe for additional ordinary shares in full after deducting the underwriting commission and estimated offering expenses payable by us, based on an assumed initial public offering price of $17.00 per ordinary share, the midpoint of the price range set forth on the cover page of this prospectus. (…) We believe that our existing cash and cash equivalents as of September 30, 2014, along with the €48 million ($60 million) of gross proceeds from our sale of our preference D shares in November 2014 and the proceeds from this offering, will be sufficient to meet our projected cash requirements for at least 12 months from the date of this prospectus,” hedder det i det foreløbige prospect.
De 100 rigeste øgede sidste år formuen med 141 mia. kr.
torsdag 30. november 2023
17:25
